Bcg polyoses nucleic acid intralipid and its cryochem formulated product and use thereof

A technology of BCG polysaccharide nucleic acid and fat emulsion, which is applied in the direction of oil/fat/wax non-effective ingredients, emulsion delivery, and medical raw materials derived from bacteria, etc., which can solve the problems of incompatible immunomodulatory drugs and achieve good timeliness Stability, improving drug bioavailability, and maintaining drug efficacy

Inactive Publication Date: 2008-01-23
高洁生
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the recommended dosage and administration time of this product are 0.5 mg each time, once every other day, which is not in line with the discontinuous administration of immunomodulatory drugs, and reforms are necessary to achieve targeted drug administration of the lymphatic system. To improve bioavailability, enhance efficacy, reduce patient pain, and save resources

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1: 5 g of refined soybean oil, 5 g of refined egg yolk lecithin, and 1 mg of BCG polysaccharide nucleic acid were heated and mixed at 40°C to 45°C; then, about 80 ml of an aqueous solution containing 10% maltose was added thereto (equivalent to 80g), stir with a homogenizer to obtain a coarse dispersion; add an aqueous solution containing 10% maltose to the obtained coarse dispersion, adjust the pH value to 7.0 with sodium hydroxide, and set the volume to 100ml. The crude dispersion was emulsified under high pressure using a Nanomizer (LA-31 type, manufactured by Nanomizer Co., Ltd.) under water cooling to obtain a homogenized very fine fat emulsion containing PGE1. The average particle size of the emulsion particles measured with a light scattering photometer is 33nm. After the obtained emulsion is filtered and sterilized through a 0.2μm membrane filter, 1ml each time is injected into 1ml ampoules, and under aseptic conditions - made into fat Emulsion or inject...

Embodiment 2

[0048] Example 2: 5 g of refined soybean oil, 5 g of refined egg yolk lecithin, and 1 mg of BCG polysaccharide nucleic acid were heated and mixed under heating conditions of 40°C to 45°C; then, about 80ml of water (equivalent to 80g) was added therein , stir with a homogenizer to obtain a coarse dispersion; add water again to the resulting coarse dispersion, adjust the pH value to 7.0 with sodium hydroxide, set the volume to 100ml, and use a Nanomizer (LA -31 type, manufactured by Nanomizer Co., Ltd.) was subjected to high-pressure emulsification of the coarse dispersion to obtain a homogenized extremely fine fat emulsion containing PGE1. Thereafter technological process is with above-mentioned embodiment 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to view more

Abstract

A bcg polyoses nucleic acid intralipid and its freeze dehydration agent and purpose are provided. The proportion for the weight shares of intralipid is: bcg polyoses nucleic acid of 0.05 to 0.5 per cent, oily component of 4 to 8 per cent, emulsifier of 3 to 8 per cent and water of 84 to 92 per cent. The oily component refers to one or more than one from plant oil, animal oil, neutral lipids, synthetic grease, sterol derivative; the emulsifier refers to the normative emulsifier in making medical preparation with the pH value of preparation liquid of 6.5 to 7.5; freeze and dry the intralipid under normal condition to make freeze dehydration agent. The invention can be applied as therapeutic agent for resisting cancer, intra-cellular infection, hypersusceptibility, cold and asthma. In the invention, the biologic reaction regulator of bcg polyoses nucleic acid is prepared as a lymph targeting preparation that can effectively regulate immunity, resisting cancer, intra-cellular infection, hypersusceptibility, cold and asthma with high efficiency and without toxic content.

Description

technical field [0001] The invention relates to a fat emulsion preparation of BCG polysaccharide nucleic acid and its freeze-drying agent and application. technical background [0002] BCG polysaccharide nucleic acid (BCG-PSN) is a new type of biological response modifier developed by the former Hunan Medical University from the 1970s to the 1990s. A large number of studies have shown that this product has strong immunoregulatory pharmacological effects such as anti-allergy, anti-intracellular infection, and anti-tumor, and it is clinically effective in preventing and treating colds and asthma. Its main mechanism of action is: (1) Inducing Th 0 Cells differentiate into Th 1 It promotes the secretion of γ-interferon (IFN-γ) and interleukin-2 (IL-2), stimulates B cells to divide into IgG2a, inhibits the synthesis of IgG1, and has immune regulation and anti-allergic effects; Nucleus-macrophage function, mice injected with this product intraperitoneally, the number of periton...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/107A61K31/715A61K35/74A61K47/42A61P35/00A61P37/08A61P11/06A61P31/00A61K47/24A61K47/28A61K47/44
Inventor 高洁生
Owner 高洁生
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap